GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Cyclically Adjusted PB Ratio

SELLAS Life Sciences Group (FRA:RXK3) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted PB Ratio?

As of today (2024-06-19), SELLAS Life Sciences Group's current share price is €1.014. SELLAS Life Sciences Group's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1,921.68. SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:RXK3's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.67
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted book value per share data for the three months ended in Mar. 2024 was €0.158. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1,921.68 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio falls into.



SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.014/1921.68
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SELLAS Life Sciences Group's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.158/131.7762*131.7762
=0.158

Current CPI (Mar. 2024) = 131.7762.

SELLAS Life Sciences Group Quarterly Data

Book Value per Share CPI Adj_Book
201406 5,288.579 100.560 6,930.313
201409 5,912.840 100.428 7,758.525
201412 6,957.176 99.070 9,253.992
201503 10,359.393 99.621 13,703.136
201506 8,160.297 100.684 10,680.287
201509 5,348.889 100.392 7,021.075
201512 2,297.222 99.792 3,033.489
201603 1,839.439 100.470 2,412.594
201606 2,974.671 101.688 3,854.835
201609 2,982.098 101.861 3,857.900
201612 -467.621 101.863 -604.945
201703 1,026.898 102.862 1,315.553
201706 682.011 103.349 869.604
201709 440.459 104.136 557.370
201712 15.164 104.011 19.212
201803 -8.685 105.290 -10.870
201806 -14.390 106.317 -17.836
201809 38.578 106.507 47.731
201812 10.465 105.998 13.010
201903 5.400 107.251 6.635
201906 6.336 108.070 7.726
201909 2.123 108.329 2.583
201912 1.080 108.420 1.313
202003 1.086 108.902 1.314
202006 0.500 108.767 0.606
202009 0.713 109.815 0.856
202012 1.612 109.897 1.933
202103 1.600 111.754 1.887
202106 1.747 114.631 2.008
202109 1.425 115.734 1.623
202112 1.133 117.630 1.269
202203 0.230 121.301 0.250
202206 0.877 125.017 0.924
202209 0.618 125.227 0.650
202212 0.218 125.222 0.229
202303 0.434 127.348 0.449
202306 0.158 128.729 0.162
202309 -0.126 129.860 -0.128
202312 -0.228 129.419 -0.232
202403 0.158 131.776 0.158

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (FRA:RXK3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines